<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.1 20050630//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Breast Cancer Res</journal-id><journal-title>Breast Cancer Research</journal-title><issn pub-type="ppub">1465-5411</issn><issn pub-type="epub">1465-542X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">bcr422</article-id><article-id pub-id-type="pmid">11879563</article-id><article-id pub-id-type="doi">10.1186/bcr422</article-id><article-categories><subj-group subj-group-type="heading"><subject>Commentary</subject></subj-group></article-categories><title-group><article-title>Are <italic>Trp53</italic> rescue of <italic>Brca1</italic> embryonic lethality and <italic>Trp53</italic>/<italic>Brca1</italic> breast cancer association related?</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>McAllister</surname><given-names>Kimberly A</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>mcallis2@niehs.nih.gov</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Wiseman</surname><given-names>Roger W</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>Laboratory of Women's Health, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA.</aff><pub-date pub-type="ppub"><year>2002</year></pub-date><pub-date pub-type="epub"><day>6</day><month>2</month><year>2002</year></pub-date><volume>4</volume><issue>2</issue><fpage>54</fpage><lpage>57</lpage><history><date date-type="received"><day>19</day><month>11</month><year>2001</year></date><date date-type="rev-request"><day>15</day><month>1</month><year>2002</year></date><date date-type="rev-recd"><day>16</day><month>1</month><year>2002</year></date><date date-type="accepted"><day>17</day><month>1</month><year>2002</year></date></history><copyright-statement>Copyright &#x000a9; 2002 BioMed Central Ltd</copyright-statement><abstract><p><italic>Brca1</italic> is involved in multiple biological pathways including DNA damage repair, transcriptional regulation, and cell-cycle progression. A complex pattern of interactions of <italic>Brca1</italic> with <italic>Trp53</italic> has also emerged. Xu and coworkers found that haploid loss of <italic>Trp53</italic> significantly reduces the embryonic lethality observed in mice with a homozygous in-frame deletion of <italic>Brca1</italic> exon 11. They report that widespread apoptosis correlates with the embryonic lethality resulting from this homozygous &#x00394;11 <italic>Brca1</italic> mutation. A mechanism responsible for <italic>Brca1</italic>-associated carcinogenesis is proposed. These experiments extend our knowledge of a complex <italic>Brca1</italic>/<italic>Trp53</italic> relationship. However, the precise mechanisms through which <italic>Brca1</italic> interacts with <italic>Trp53</italic> to suppress mammary tumor formation have yet to be elucidated.</p></abstract><kwd-group><kwd>apoptosis</kwd><kwd><italic>Brca1</italic></kwd><kwd>breast cancer</kwd><kwd><italic>Trp53</italic></kwd><kwd>tumorigenesis</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p><italic>Brca1</italic> appears to have a role in multiple complex biological pathways including DNA damage repair, transcriptional regulation, and cell-cycle checkpoint control. <italic>Brca1</italic> is thought to function as a caretaker that is responsible for maintaining genomic integrity [<xref ref-type="bibr" rid="B1">1</xref>]. Loss of <italic>Brca1</italic> function has been shown to lead to defective DNA repair, to defective G<sub>2</sub>-M cell-cycle checkpoints, to increased apoptosis, and to genomic instability. This generalized genetic instability is thought to lead to the accumulation of additional mutations that eventually allow <italic>Brca1</italic>-deficient cells to undergo neoplastic transformation (reviewed in [<xref ref-type="bibr" rid="B2">2</xref>]). Perhaps the most intriguing role of <italic>Brca1</italic>, however, is its complex interaction with <italic>Trp53</italic>.</p><p>The recent study by Xu <italic>et al</italic>. attempts to clarify our understanding of the complicated <italic>Trp53</italic>/<italic>Brca1</italic> relationship [<xref ref-type="bibr" rid="B3">3</xref>]. Substantial evidence suggests that <italic>Brca1</italic> and <italic>Trp53</italic> appear to be linked in their roles as tumor suppressor genes. <italic>Brca1</italic> and <italic>Trp53</italic> are coordinately regulated in their gene expression [<xref ref-type="bibr" rid="B4">4</xref>]. <italic>Brca1</italic> physically associates with <italic>Trp53</italic> and stimulates its transcriptional activity [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>]. The <italic>Trp53</italic> protein appears to regulate <italic>Brca1</italic> expression levels [<xref ref-type="bibr" rid="B7">7</xref>], while <italic>Brca1</italic> in turn upregulates <italic>p21</italic>[<xref ref-type="bibr" rid="B8">8</xref>]. <italic>Brca1</italic> loss therefore triggers the <italic>Trp53</italic>-<italic>Cdkn1a</italic>-mediated cell-cycle checkpoint and corresponding cell death [<xref ref-type="bibr" rid="B9">9</xref>]. Finally, <italic>Trp53</italic> loss appears to enhance <italic>Brca1</italic>-linked tumorigenesis [<xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B12">12</xref>].</p></sec><sec><title><italic>Trp53</italic> rescue of <italic>Brca1</italic> embryonic lethality</title><p>The specific role of <italic>Trp53</italic> in rescue of embryonic lethality of mice with various <italic>Brca1</italic> mutations remains unclear. Earlier studies have shown that <italic>Trp53</italic> and <italic>Cdkn1a</italic> deficiencies can extend the development of several severe <italic>Brca1</italic> mutations [<xref ref-type="bibr" rid="B13">13</xref>-<xref ref-type="bibr" rid="B15">15</xref>]. Xu <italic>et al.</italic>[<xref ref-type="bibr" rid="B3">3</xref>] found that haploid loss of <italic>Trp53</italic> significantly rescues the embryonic lethality resulting from a <italic>Brca1</italic><sup>&#x00394;11/&#x00394;11</sup> mutation. These <italic>Brca1</italic><sup>&#x00394;11/&#x00394;11</sup> embryos normally die during late gestation in a wild-type <italic>Trp53</italic> background. With p53 haploinsufficiency, however, approximately 80% of the expected <italic>Brca1</italic><sup>&#x00394;11/&#x00394;11</sup><italic>Trp53</italic><sup>+/-</sup> mice survive based on Mendelian ratios for offspring from a double heterozygous cross. Unfortunately, Xu <italic>et al</italic>. [<xref ref-type="bibr" rid="B3">3</xref>] failed to note that the <italic>Brca1</italic> and <italic>Trp53</italic> loci reside within 20 cM of each other on mouse chromosome 11. These loci are therefore closely linked and do not recombine independently, as they would if located on different chromosomes. To determine the predicted genotypic distribution of offspring, the phase of the mutant <italic>Brca1</italic> and <italic>Trp53</italic> alleles on the parental chromosomes used in this intercross must be known. The expected numbers of specific genotypes in the offspring will differ widely depending on whether the mutant <italic>Brca1</italic> and <italic>Trp53</italic> alleles were present in cis versus trans configurations in the parental chromosomes.</p><p>Two other groups have described mice with related hypo-morphic mutant <italic>Brca1</italic> alleles that remove all or part of exon 11 while preserving the &#x00394;11 exon splice variant that produces a truncated <italic>Brca1</italic> protein. Cressman <italic>et al.</italic>[<xref ref-type="bibr" rid="B16">16</xref>] described three mice homozygous for both a mutant <italic>Trp53</italic> and a <italic>Brca1</italic> alteration that normally results in late embryonic lethality in the homozygous state. These authors propose that other genetic factors in addition to <italic>Trp53</italic> loss may be required for the survival of these <italic>Brca1</italic>-mutant mice. It is interesting to speculate that DBA/2-specific alleles may be involved since the DBA/2 genetic background also appears to enhance survival of hypomorphic <italic>Brca2</italic> mutants [<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B18">18</xref>].</p><p>Ludwig <italic>et al</italic>. have generated mice with a related hypomorphic <italic>Brca1</italic> mutation [<xref ref-type="bibr" rid="B19">19</xref>], which was viable in particular genetic backgrounds in the absence of any additional <italic>Trp53</italic> mutation. This exon 11 mutation was predicted to lead to the truncation of the <italic>Brca1</italic> protein after the first 924 amino acids. This mutant <italic>Brca1</italic> protein is unique since it retains the nuclear localization signals in exon 11 as well as a proposed <italic>Trp53</italic> interaction domain between residues 224 and 500 [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B5">5</xref>]. However, a &#x00394;11 splice variant protein is also still expressed in these mice as with mutants from the other groups. From original intercrosses between 129/Sv &#x000d7; C57BL/6J heterozygous parents, Ludwig <italic>et al</italic>. found only 4% homozygous <italic>Brca1</italic> mutants compared with the expected 25%. After backcrossing with 129/Sv mice or outcrossing to the MF1 strain, however, these investigators reported complete restoration of Mendelian ratios. These <italic>Brca1</italic> mutant mice thus appeared to have a more complete rescue of embryonic lethality based on genetic background differences alone than Xu <italic>et al.</italic> were able to obtain by introducing <italic>Trp53</italic> haploinsufficiency. Unfortunately, Xu <italic>et al</italic>. did not provide any information about the genetic background of their mutant mice. This dramatic difference in explanations for the embryonic lethality 'rescue' of these similar <italic>Brca1</italic> mutations is difficult to reconcile.</p><p>Xu <italic>et al</italic>. state that a major finding of the study was the ability to demonstrate the widespread apoptosis of <italic>Brca1</italic>-deficient embryos and the lack of this apoptosis in the <italic>Brca1</italic> mutants with <italic>Trp53</italic> mutations [<xref ref-type="bibr" rid="B3">3</xref>]. They propose that the apoptotic process normally triggered by <italic>Brca1</italic> loss does not occur with <italic>Trp53</italic> haploinsufficiency due to loss of the critical G<sub>1</sub>-S checkpoint control. Cells with <italic>Brca1</italic> mutations that have accumulated DNA damage are therefore allowed to proliferate rather than undergo apoptosis. Xu <italic>et al</italic>. suggest this difference in apoptosis is a plausible explanation for the rescue of the embryonic lethality of these <italic>Brca1</italic> mutants. However, the rescue of <italic>Brca1</italic><sup>&#x00394;11/&#x00394;11</sup> embryos did not occur when single downstream pathways of p53 were disrupted by eliminating either <italic>Bax</italic> or <italic>Cdkn1a</italic>.</p></sec><sec><title>Mammary tumorigenesis association with combined <italic>Trp53/Brca1</italic> deficiency</title><p>Multiple studies have now suggested that <italic>Trp53</italic> loss accelerates mammary tumor formation when associated with <italic>Brca1</italic> mutations. Although quantitative data was not presented in this report, Xu <italic>et al</italic>. [<xref ref-type="bibr" rid="B3">3</xref>] state that most of their female <italic>Brca1</italic><sup>&#x00394;11/&#x00394;11</sup> mice that carried a <italic>Trp53</italic> mutation developed mammary tumors with loss of the remaining <italic>Trp53</italic> allele by 6&#x02013;12 months of age. Ludwig <italic>et al.</italic>[<xref ref-type="bibr" rid="B13">13</xref>] found that many of their homozygous <italic>Brca1</italic>-mutant mice also developed mammary tumors as well as a wide variety of other tumors. They also investigated whether <italic>Trp53</italic> deficiency affected this <italic>Brca1</italic>-associated tumorigenesis, and observed accelerated tumorigenesis in mice carrying both mutations.</p><p><italic>Trp53</italic> hemizygosity allowed mice with the <italic>Brca1</italic> mutation developed by Cressman <italic>et al</italic>. [<xref ref-type="bibr" rid="B11">11</xref>] to develop a few mammary tumors after exposure to ionizing radiation, although these results did not achieve statistical significance. In contrast, mice with this <italic>Brca1</italic> mutation on a wild-type <italic>Trp53</italic> background did not develop mammary tumors. Finally, there was a decreased latency and increased incidence of mammary tumor formation in conditionally mutant <italic>Brca1</italic> mice that had a <italic>Trp53</italic> mutation [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B20">20</xref>]. A high frequency of <italic>Trp53</italic> mutations has also been observed in human BRCA-linked tumors. Some of these <italic>Trp53</italic> mutations are unique or unusual, suggesting that the tumorigenesis pathway mediated by combined <italic>Brca1</italic>/<italic>Trp53</italic> mutations may be different to the pathway for other <italic>Trp53</italic>-mediated tumorigenesis, such as what is observed in Li-Fraumini syndrome [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B22">22</xref>].</p></sec><sec><title>Biological pathway of the <italic>Trp53/Brca1</italic> interaction</title><p>Xu <italic>et al.</italic> attempted to further elucidate the molecular interaction between <italic>Trp53</italic> and <italic>Brca1</italic> that might lead to tumorigenesis in the <italic>Brca1</italic><sup>&#x00394;11/&#x00394;11</sup> mice [<xref ref-type="bibr" rid="B3">3</xref>]. <italic>Trp53</italic> was found to have decreased stability in the <italic>Brca1</italic><sup>&#x00394;11/&#x00394;11</sup> background after treatment with exogenous DNA damaging agents. Increased <italic>Mdm2</italic> levels and decreased phosphorylation of <italic>Trp53</italic> at Ser18 in &#x003b3;-irradiated <italic>Brca1</italic><sup>&#x00394;11/&#x00394;11</sup> mutant cells were suggested to be the primary causes for the decreased stability of <italic>Trp53</italic> in these cells. Xu <italic>et al</italic>. propose that this decreased stability of <italic>Trp53</italic> after stress-induced DNA damage might allow additional mutations to accumulate. Ultimately, such genetic alterations may allow the proliferation defect of <italic>Brca1</italic> deficiency to be overcome, and <italic>Brca1</italic>-associated tumorigenesis will result.</p></sec><sec><title>Conclusions</title><p>Although the report by Xu <italic>et al.</italic> has contributed to our understanding of the <italic>Brca1</italic>/<italic>Trp53</italic> relationship, a number of key questions remain to be addressed.</p><sec><title>Why a rescue of <italic>Brca1</italic>-deficient embryonic lethality with Trp53?</title><p>The authors propose the substantial difference found in apoptosis between <italic>Brca1</italic><sup>&#x00394;11/&#x00394;11</sup> mutant cells with or without <italic>Trp53</italic> mutations is a logical explanation for the rescue of the embryonic lethality of these <italic>Brca1</italic> mutants. However, several studies suggest that <italic>Brca1</italic> mutant embryos in which the <italic>Trp53</italic>-mediated apoptotic pathway is intact do not necessarily have an increase in apoptosis [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B16">16</xref>]. In addition, the rescue of <italic>Brca1</italic><sup>&#x00394;11/&#x00394;11</sup> embryos did not occur when disrupting single downstream pathways of <italic>Trp53</italic>. This suggests that the process through which <italic>Trp53</italic> might allow for an extension of survival of <italic>Brca1</italic> mutants must involve either multiple <italic>Trp53</italic>-mediated pathways or additional genetic pathways altogether.</p></sec><sec><title>What is the relationship between BRCA1 and <italic>Trp53</italic> mutations that leads specifically to mammary tumor development?</title><p>The basis for the tissue specificity for <italic>Brca1</italic>/<italic>Trp53</italic> tumorigenesis remains unknown. It is interesting that the incidence of mammary tumors in <italic>Trp53</italic>-deficient mice appears to be dependent on genetic background strain [<xref ref-type="bibr" rid="B23">23</xref>]. This suggests that different sets of modifier loci in different inbred strains of mice impact the effect of the loss of <italic>Trp53</italic> in specific cell types or tissues. Other studies have shown that the type of tumor resulting from <italic>Trp53</italic> loss can differ dramatically depending on the tissue type and the oncogenic pathway involved [<xref ref-type="bibr" rid="B2">2</xref>]. In mammary tumorigenesis, it has been suggested that BRCA1 and <italic>Trp53</italic> deficiencies cooperate only with exposure of the mammary gland to DNA damage [<xref ref-type="bibr" rid="B11">11</xref>]. Alternatively, a lack of downstream mediators in tissues other than ovarian and mammary glands has been suggested to explain the tissue-specificity of <italic>Brca1</italic>-associated tumorigenesis [<xref ref-type="bibr" rid="B2">2</xref>].</p></sec><sec><title>Are the molecular mechanisms for the <italic>Trp53</italic> rescue of <italic>Brca1</italic> embryonic lethality and the <italic>Trp53</italic>-mediated acceleration of <italic>Brca1</italic>-induced mammary tumorigenesis the same?</title><p>Even if one assumes that <italic>Trp53</italic>-mediated apoptosis is significantly relevant for the mechanism of <italic>Trp53</italic> rescue of <italic>Brca1</italic> lethality, it is unclear how this <italic>Trp53</italic> mechanism relates to tumorigenesis due to <italic>Trp53</italic> loss. Although some studies clearly demonstrate the association of loss of <italic>Trp53</italic> with loss of apoptosis in developing tumors, other studies do not find this correlation, suggesting that p53 loss might alter tumor progression by different mechanisms in different cell types or tumor pathways [<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B25">25</xref>]. In fact, some evidence suggests that the multiple functions of <italic>Trp53</italic> as a tumor suppressor, apoptosis inducer, and cell-cycle regulator may be entirely independent from each other [<xref ref-type="bibr" rid="B26">26</xref>]. Future directions to begin to establish the downstream partners and pathways involved in <italic>Brca1</italic>/<italic>Trp53</italic> tumorigenesis will clearly be necessary to answer these questions.</p></sec></sec></body><back><ack><sec><title>Acknowledgements</title><p>The authors thank Dr Cynthia Afshari and Dr Deborah Swope for the critical review of this manuscript.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kinzler</surname><given-names>KW</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name></person-group><article-title>Cancer-susceptibility genes. Gatekeepers and caretakers.</article-title><source>Nature</source><year>1997</year><volume>386</volume><fpage>761</fpage><lpage>763</lpage><pub-id pub-id-type="pmid">9126728</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>C-X</given-names></name><name><surname>Brodie</surname><given-names>SG</given-names></name></person-group><article-title>Roles of BRCA1 and its interacting proteins.</article-title><source>BioEssays</source><year>2000</year><volume>22</volume><fpage>728</fpage><lpage>737</lpage><pub-id pub-id-type="pmid">10918303</pub-id><pub-id pub-id-type="doi">10.1002/1521-1878(200008)22:8&#x0003c;728::AID-BIES6&#x0003e;3.3.CO;2-2</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Qiao</surname><given-names>W</given-names></name><name><surname>Linke</surname><given-names>SP</given-names></name><name><surname>Cao</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>W-M</given-names></name><name><surname>Furth</surname><given-names>PA</given-names></name><name><surname>Harris</surname><given-names>CC</given-names></name><name><surname>Deng</surname><given-names>C-X</given-names></name></person-group><article-title>Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle, and tumorigenesis.</article-title><source>Nat Genet</source><year>2001</year><volume>28</volume><fpage>266</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">11431698</pub-id><pub-id pub-id-type="doi">10.1038/90108</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ouchi</surname><given-names>T</given-names></name><name><surname>Monteiro</surname><given-names>ANA</given-names></name><name><surname>August</surname><given-names>A</given-names></name><name><surname>Aaronson</surname><given-names>SA</given-names></name><name><surname>Hanafusa</surname><given-names>H</given-names></name></person-group><article-title>BRCA1 regulates p53-dependent gene expression.</article-title><source>PNAS</source><year>1998</year><volume>95</volume><issue>5</issue><fpage>2302</fpage><lpage>2306</lpage><pub-id pub-id-type="pmid">9482880</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>HB</given-names></name><name><surname>Somasundaram</surname><given-names>K</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Tian</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>HX</given-names></name><name><surname>Bi</surname><given-names>DK</given-names></name><name><surname>Weber</surname><given-names>BL</given-names></name><name><surname>el-Deiry</surname><given-names>WS</given-names></name></person-group><article-title>BRCA1 physically associates with p53 and stimulates its transcriptional activity.</article-title><source>Oncogene</source><year>1998</year><volume>16</volume><issue>13</issue><fpage>1713</fpage><lpage>1721</lpage><pub-id pub-id-type="pmid">9582019</pub-id><pub-id pub-id-type="doi">10.1038/sj/onc/1201932</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chai</surname><given-names>YL</given-names></name><name><surname>Cui</surname><given-names>JQ</given-names></name><name><surname>Shao</surname><given-names>NS</given-names></name><name><surname>Reddy</surname><given-names>ESP</given-names></name><name><surname>Rao</surname><given-names>VN</given-names></name></person-group><article-title>The second BRCT domain of BRCA1 protein interacts with p53 and stimulates transcription from the p21(WAF1/CIP1) promoter.</article-title><source>Oncogene</source><year>1999</year><volume>18</volume><issue>1</issue><fpage>263</fpage><lpage>268</lpage><pub-id pub-id-type="pmid">9926942</pub-id><pub-id pub-id-type="doi">10.1038/sj/onc/1202323</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andres</surname><given-names>JL</given-names></name><name><surname>Saijun</surname><given-names>F</given-names></name><name><surname>Turkel</surname><given-names>GJ</given-names></name><name><surname>Wang</surname><given-names>J-A</given-names></name><name><surname>Twu</surname><given-names>N-F</given-names></name><name><surname>Yuan</surname><given-names>R-Q</given-names></name><name><surname>Lamszus</surname><given-names>K</given-names></name><name><surname>Goldberg</surname><given-names>ID</given-names></name><name><surname>Rosen</surname><given-names>EM</given-names></name></person-group><article-title>Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents.</article-title><source>Oncogene</source><year>1998</year><volume>16</volume><fpage>2229</fpage><lpage>2241</lpage><pub-id pub-id-type="pmid">9619832</pub-id><pub-id pub-id-type="doi">10.1038/sj/onc/1201752</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>MacLachlan</surname><given-names>TK</given-names></name><name><surname>Dash</surname><given-names>BC</given-names></name><name><surname>Dicker</surname><given-names>DT</given-names></name><name><surname>El-Deiry</surname><given-names>WS</given-names></name></person-group><article-title>Repression of BRCA1 through a feedback loop involving p53.</article-title><source>J Biol Chem</source><year>2000</year><volume>275</volume><issue>41</issue><fpage>31869</fpage><lpage>31875</lpage><pub-id pub-id-type="pmid">10884389</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Somasundaram</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zeng</surname><given-names>YX</given-names></name><name><surname>Houvras</surname><given-names>Y</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>GS</given-names></name><name><surname>Licht</surname><given-names>JD</given-names></name><name><surname>Weber</surname><given-names>BL</given-names></name><name><surname>el-Deiry</surname><given-names>WS</given-names></name></person-group><article-title>Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1.</article-title><source>Nature</source><year>1997</year><volume>389</volume><fpage>187</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">9296497</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Greenblatt</surname><given-names>MS</given-names></name><name><surname>Chappuis</surname><given-names>PO</given-names></name><name><surname>Bond</surname><given-names>JP</given-names></name><name><surname>Hamel</surname><given-names>N</given-names></name><name><surname>Foulkes</surname><given-names>WD</given-names></name></person-group><article-title>TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: Distinctive spectrum and structural distribution.</article-title><source>Cancer Res</source><year>2001</year><volume>61</volume><issue>10</issue><fpage>4092</fpage><lpage>4097</lpage><pub-id pub-id-type="pmid">11358831</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cressman</surname><given-names>VL</given-names></name><name><surname>Backlund</surname><given-names>DC</given-names></name><name><surname>Hicks</surname><given-names>EM</given-names></name><name><surname>Gowen</surname><given-names>LC</given-names></name><name><surname>Godfrey</surname><given-names>V</given-names></name><name><surname>Koller</surname><given-names>BH</given-names></name></person-group><article-title>Mammary tumor formation in p53- and BRCA1-deficient mice.</article-title><source>Cell Growth Differ</source><year>1999</year><volume>10</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">9950212</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Wagner</surname><given-names>K-U</given-names></name><name><surname>Larson</surname><given-names>D</given-names></name><name><surname>Weaver</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Ried</surname><given-names>T</given-names></name><name><surname>Hennighausen</surname><given-names>L</given-names></name><name><surname>Wynshaw-Boris</surname><given-names>A</given-names></name><name><surname>Deng</surname><given-names>C-X</given-names></name></person-group><article-title>Conditional mutant of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation.</article-title><source>NatGenet</source><year>1999</year><volume>22</volume><fpage>37</fpage><lpage>42</lpage></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ludwig</surname><given-names>T</given-names></name><name><surname>Chapman</surname><given-names>DL</given-names></name><name><surname>Papaioannou</surname><given-names>VE</given-names></name><name><surname>Efstratiadis</surname><given-names>A</given-names></name></person-group><article-title>Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos.</article-title><source>Genes Dev</source><year>1997</year><volume>11</volume><issue>10</issue><fpage>1226</fpage><lpage>1241</lpage><pub-id pub-id-type="pmid">9171368</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hakem</surname><given-names>R</given-names></name><name><surname>de la Pompa</surname><given-names>JL</given-names></name><name><surname>Sirard</surname><given-names>C</given-names></name><name><surname>Mo</surname><given-names>R</given-names></name><name><surname>Woo</surname><given-names>M</given-names></name><name><surname>Hakem</surname><given-names>A</given-names></name><name><surname>Wakeham</surname><given-names>A</given-names></name><name><surname>Potter</surname><given-names>J</given-names></name><name><surname>Reitmair</surname><given-names>A</given-names></name><name><surname>Billia</surname><given-names>F</given-names></name><name><surname>Firpo</surname><given-names>E</given-names></name><name><surname>Hui</surname><given-names>CC</given-names></name><name><surname>Roberts</surname><given-names>J</given-names></name><name><surname>Rossant</surname><given-names>J</given-names></name><name><surname>Mak</surname><given-names>TW</given-names></name></person-group><article-title>The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse.</article-title><source>Cell</source><year>1996</year><volume>85</volume><fpage>1009</fpage><lpage>1023</lpage><pub-id pub-id-type="pmid">8674108</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hakem</surname><given-names>R</given-names></name><name><surname>de la Pompa</surname><given-names>JL</given-names></name><name><surname>Eli</surname><given-names>A</given-names></name><name><surname>Potter</surname><given-names>J</given-names></name><name><surname>Mak</surname><given-names>TW</given-names></name></person-group><article-title>Partial rescue of Brca1(5-6) early embryonic lethality by p53 or p21 null mutation.</article-title><source>Nat Genet</source><year>1997</year><volume>16</volume><issue>3</issue><fpage>298</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">9207798</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cressman</surname><given-names>VL</given-names></name><name><surname>Backlund</surname><given-names>DC</given-names></name><name><surname>Avrutskaya</surname><given-names>AV</given-names></name><name><surname>Leadon</surname><given-names>SA</given-names></name><name><surname>Godfrey</surname><given-names>V</given-names></name><name><surname>Koller</surname><given-names>BH</given-names></name></person-group><article-title>Growth retardation, DNA repair defects, and lack of spermatogenesis in BRCA1-deficient mice.</article-title><source>Mol Cell Biol</source><year>1999</year><volume>19</volume><fpage>7061</fpage><lpage>7075</lpage><pub-id pub-id-type="pmid">10490643</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Connor</surname><given-names>F</given-names></name><name><surname>Bertwistle</surname><given-names>D</given-names></name><name><surname>Mee</surname><given-names>PJ</given-names></name><name><surname>Ross</surname><given-names>GM</given-names></name><name><surname>Swift</surname><given-names>S</given-names></name><name><surname>Grigorieva</surname><given-names>E</given-names></name><name><surname>Tybulewicz</surname><given-names>VLJ</given-names></name><name><surname>Ashworth</surname><given-names>A</given-names></name></person-group><article-title>Tumorigenesis and a DNA repair defect in mice with a truncating <italic>Brca2</italic> mutation.</article-title><source>Nat Genet</source><year>1997</year><volume>17</volume><fpage>423</fpage><lpage>430</lpage><pub-id pub-id-type="pmid">9398843</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>LS</given-names></name><name><surname>Thistlewaite</surname><given-names>FC</given-names></name><name><surname>Pael</surname><given-names>KJ</given-names></name><name><surname>Yu</surname><given-names>VPCC</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Venkitar-man</surname><given-names>AR</given-names></name><name><surname>Abel</surname><given-names>KJ</given-names></name><name><surname>Carlton</surname><given-names>MBL</given-names></name><name><surname>Hunter</surname><given-names>SM</given-names></name><name><surname>Colledge</surname><given-names>WH</given-names></name><name><surname>Evans</surname><given-names>MJ</given-names></name><name><surname>Ponder</surname><given-names>BAJ</given-names></name></person-group><article-title>Thymic lymphomas in mice with a truncating mutation in <italic>Brca2</italic>.</article-title><source>Cancer Res</source><year>1998</year><volume>58</volume><fpage>1338</fpage><lpage>1343</lpage><pub-id pub-id-type="pmid">9537225</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ludwig</surname><given-names>T</given-names></name><name><surname>Fisher</surname><given-names>P</given-names></name><name><surname>Ganesan</surname><given-names>S</given-names></name><name><surname>Efstratiadis</surname><given-names>A</given-names></name></person-group><article-title>Tumorigenesis in mice carrying a truncating <italic>Brca1</italic> mutation.</article-title><source>Genes Dev</source><year>2001</year><volume>15</volume><fpage>1188</fpage><lpage>1193</lpage><pub-id pub-id-type="pmid">11358863</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brodie</surname><given-names>SG</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Qiao</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>WM</given-names></name><name><surname>Cao</surname><given-names>L</given-names></name><name><surname>Deng</surname><given-names>CX</given-names></name></person-group><article-title>Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice.</article-title><source>Oncogene</source><year>2001</year><volume>20</volume><fpage>7514</fpage><lpage>7523</lpage><pub-id pub-id-type="pmid">11709723</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Crook</surname><given-names>T</given-names></name><name><surname>Brooks</surname><given-names>LA</given-names></name><name><surname>Crossland</surname><given-names>S</given-names></name><name><surname>Osin</surname><given-names>P</given-names></name><name><surname>Barker</surname><given-names>KT</given-names></name><name><surname>Waller</surname><given-names>J</given-names></name><name><surname>Philp</surname><given-names>E</given-names></name><name><surname>Smith</surname><given-names>PD</given-names></name><name><surname>Yulug</surname><given-names>I</given-names></name><name><surname>Peto</surname><given-names>J</given-names></name><name><surname>Parker</surname><given-names>G</given-names></name><name><surname>Allday</surname><given-names>MJ</given-names></name><name><surname>Crompton</surname><given-names>MR</given-names></name><name><surname>Gusterson</surname><given-names>BA</given-names></name></person-group><article-title>P53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours.</article-title><source>Oncogene</source><year>1998</year><volume>17</volume><fpage>1681</fpage><lpage>1689</lpage><pub-id pub-id-type="pmid">9796697</pub-id><pub-id pub-id-type="doi">10.1038/sj/onc/1202106</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>PD</given-names></name><name><surname>Crossland</surname><given-names>S</given-names></name><name><surname>Parker</surname><given-names>G</given-names></name><name><surname>Osin</surname><given-names>P</given-names></name><name><surname>Brooks</surname><given-names>L</given-names></name><name><surname>Waller</surname><given-names>J</given-names></name><name><surname>Philp</surname><given-names>E</given-names></name><name><surname>Crompton</surname><given-names>MR</given-names></name><name><surname>Gusterson</surname><given-names>BA</given-names></name><name><surname>Allday</surname><given-names>MJ</given-names></name><name><surname>Crook</surname><given-names>T</given-names></name></person-group><article-title>Novel p53 mutations selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions.</article-title><source>Oncogene</source><year>1999</year><volume>18</volume><fpage>2451</fpage><lpage>2459</lpage><pub-id pub-id-type="pmid">10229196</pub-id><pub-id pub-id-type="doi">10.1038/sj/onc/1202565</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuperwasser</surname><given-names>C</given-names></name><name><surname>Hurlbut</surname><given-names>GD</given-names></name><name><surname>Kittrell</surname><given-names>FS</given-names></name><name><surname>Dickinson</surname><given-names>ES</given-names></name><name><surname>Laucirica</surname><given-names>R</given-names></name><name><surname>Medina</surname><given-names>D</given-names></name><name><surname>Naber</surname><given-names>SP</given-names></name><name><surname>Jerry</surname><given-names>DJ</given-names></name></person-group><article-title>Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome.</article-title><source>Am J Pathol</source><year>2000</year><volume>157</volume><fpage>2151</fpage><lpage>2159</lpage><pub-id pub-id-type="pmid">11106587</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Symonds</surname><given-names>H</given-names></name><name><surname>Krall</surname><given-names>L</given-names></name><name><surname>Remington</surname><given-names>L</given-names></name><name><surname>Saenz-Robles</surname><given-names>M</given-names></name><name><surname>Lowe</surname><given-names>S</given-names></name><name><surname>Jacks</surname><given-names>T</given-names></name><name><surname>Van Dyke</surname><given-names>T</given-names></name></person-group><article-title><italic>p53-dependent apoptosis suppresses tumor growth and progression in vivo.</italic></article-title><source>Cell</source><year>1994</year><volume>78</volume><fpage>703</fpage><lpage>711</lpage><pub-id pub-id-type="pmid">8069917</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>JM</given-names></name><name><surname>Attardi</surname><given-names>L</given-names></name><name><surname>Godley</surname><given-names>LA</given-names></name><name><surname>Laucirica</surname><given-names>R</given-names></name><name><surname>Medina</surname><given-names>D</given-names></name><name><surname>Jacks</surname><given-names>T</given-names></name><name><surname>Varmus</surname><given-names>HE</given-names></name><name><surname>Donehower</surname><given-names>LA</given-names></name></person-group><article-title>Absence of p53 in a mouse mammary tumor model promotes tumor cell proliferation without affecting apoptosis.</article-title><source>Cell Growth Differ</source><year>1997</year><volume>8</volume><fpage>829</fpage><lpage>838</lpage><pub-id pub-id-type="pmid">9269892</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Macleod</surname><given-names>KF</given-names></name><name><surname>Jacks</surname><given-names>T</given-names></name></person-group><article-title>Insights into cancer from transgenic mouse models.</article-title><source>J Pathol</source><year>1999</year><volume>187</volume><fpage>43</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">10341706</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1096-9896(199901)187:1&#x0003c;43::AID-PATH246&#x0003e;3.0.CO;2-P</pub-id></citation></ref></ref-list></back></article> 